Category: Bedfont news

Bedfont® becomes the first compassionate workplace accredited in Kent

Posted on

Embedding compassion into policies, practices and everyday actions.

Bedfont® Scientific Ltd. is a world leader in breath analysis, with over 49 years of expertise in designing and manufacturing medical devices. The innovative med-tech company, based in Harrietsham, was proud to receive the Compassionate Workplace accreditation from Heart of Kent Hospice, in partnership with Compassionate Communities UK, in December 2025.

Compassionate Communities UK is a UK charity dedicated to embedding compassion into everyday life, including workplaces. The charity is collaborating with various organisations, helping employers ensure they operate in a compassionate way for staff who are dealing with bereavement, death and loss or those who may be facing a terminal illness themselves.

Heart of Kent Hospice, a charity-run hospice providing specialist palliative and end-of-life care for adults, as well as their families, carers and loved ones, is supporting employers in the local area with the tools and confidence to have compassionate conversations about end-of-life, loss and bereavement in the workplace. They were thrilled to have awarded Bedfont® with the Compassionate Workplace accreditation in December 2025.

David Dadswell, Corporate Partnerships Manager at Heart of Kent Hospice, said, “Bedfont’s commitment to becoming the first accredited Compassionate Workplace is a powerful statement. By recognising the realities of grief, caring and serious illness, they are setting a new standard for what a truly supportive employer looks like. Prioritising compassion at work will make a meaningful difference to their staff and families across our community.”

Having supported the hospice since 2023, sponsoring its flagship Bluebell Walk events and Shaun the Sheep trail, Bedfont® joined Heart of Kent Hospice for a roundtable discussion to identify areas where the hospice could provide support, such as signposting and delivering training. During the accreditation process, it was highlighted that some areas of the business required improvement, and the hospice subsequently delivered a group training session focused on those areas.

Compassionate Workplace

After completing the assessment, Bedfont® became the first business in Kent to achieve Compassionate Workplace status, underscoring the company’s commitment to providing an environment where every staff member feels valued, supported and heard.

“Receiving the Compassionate Workplace accreditation is a deeply meaningful milestone for us.” Said Jason Smith, CEO at Bedfont® Scientific. “As the first organisation in Kent to achieve this recognition, we feel both proud and responsible to lead by example. At the heart of our organisation are people, and we believe work should be a place of understanding, dignity and care, particularly during life’s most challenging moments. This accreditation strengthens our commitment to creating a culture where compassion is embedded in our leadership, our policies and our everyday actions.”

Already committed to employee wellbeing, Bedfont® has strengthened its offerings for staff, equipping them with the knowledge and tools to approach difficult conversations and support those dealing with bereavement or terminal illness.

To learn more about Bedfont® and its support of Heart of Kent Hospice, visit the website here, and follow them on LinkedIn.

Championing Innovation: Bedfont® Scientific CTO Shortlisted for Technology Leader of the Year

Posted on

Shortlisting recognises Bedfont’s role in driving innovation and technology leadership across Kent.

Bedfont CTO Shortlisted at National Technology Awards

Scott Deamer-Smith, Chief Technology Officer (CTO) at Bedfont® Scientific Limited, has been recognised for his outstanding contribution to innovation and technology. Scott has spent an impressive 18 years of his career at Bedfont®, a med-tech company which specialises in the development of medical breath analysis devices and is thrilled to have been shortlisted in the Technology Leader of the Year category at this year’s National Technology Awards.

The awards are an annual UK programme hosted by National Technology News, designed to celebrate outstanding achievement and innovations in the technology sector. It spotlights companies, projects, products and leaders that drive technological progress and transformation across industries.

Scott Deamer-Smith, Chief Technology Officer at Bedfont® Scientific, comments, “I’m honoured to be recognised in the Technology Leader of the Year category and see it as a reflection of the strength of the team around me. At Bedfont®, innovation is something we create together every day, built on empowering people, encouraging curiosity & supporting bold ideas. This shortlisting represents the shared commitment & dedication of our technical team & the wider business. I’m incredibly proud of what we continue to accomplish together.”

To be considered in the Technology Leader of the Year category, individuals must demonstrate how they lead by example and inspire those around them to tackle the issues facing their business with innovative strategies and thoughtful staff development. Scott leads the technical department at Bedfont®, and its success is very much the result of his continued vision and commitment to driving technology development across the business.

“I count myself incredibly lucky to have seen Scott evolve since we were kids. Even back then, he was beating everyone in class with his technical prowess.” Said Jason Smith, CEO at Bedfont®. “Bedfont® has benefited enormously from his big brain, relentless curiosity and determination to push boundaries. If the judges manage to glean even a small part of the contribution he’s made, not just to our company, but to the wider industry, then there’s really only one winner.”

Bedfont®, a world leader in breath analysis, is incredibly proud of Scott’s achievement. The innovative med-tech company prides itself on staff development and actively encourages career growth with a dedicated training budget available to all staff. Scott joined Bedfont® in 2007 as an IT and Technical Support Engineer and, throughout his career at Bedfont®, has been given numerous opportunities to advance, culminating in his leadership of the technical department as Chief Technology Officer.

Winners will be announced at the awards ceremony on Thursday, 14th May at the London Marriott Hotel, where leading businesses and individuals will gather to celebrate this year’s outstanding achievements. To learn more about Bedfont® and its commitment to innovation, visit the website here.

Creating space to thrive: Bedfont® supports school library revamp

Posted on

A collective community effort helps breathe new life into a much-loved school space.

Bedfont® Scientific Limited, a local med-tech business located in Harrietsham, was pleased to help create a tranquil woodland-themed library for children at Harrietsham Church of England Primary School. The library space, which had been used as a flow-through area with no real purpose until 2 years ago, was created for children to enjoy during lunchtime; however, it lacked a certain magic. With tight educational budgets, the school asked for help and set out to revamp the school library.

When the school reached out to local businesses for support in revitalising its library, Bedfont® was proud to step forward. Over a couple of weeks, a dedicated team of Bedfont® volunteers worked side by side with school staff and family members to transform the space with a fresh coat of paint. The collaborative effort not only refreshed the physical environment but also helped create a brighter, more welcoming space that inspires students and encourages a love of reading.

“The physical environment plays a significant role in supporting young people’s wellbeing,” said Claire Dadswell, Wellbeing Manager at Bedfont®. “By helping to refresh the library, we’ve contributed to a space that encourages creativity, focus and a love of reading. It’s wonderful to know that students will benefit from this transformation for years to come.”

Bedfont® Supports School Library Revamp
Bedfont® supports school library revamp

Much of the library’s transformation was made possible through generous community support. The furniture was kindly donated by a library that was closing its doors, while the greenery used to bring the woodland theme to life was provided by online retailer Blooming Artificial. After discovering a striking feature tree on Facebook Marketplace, the school organised a ‘Wear It Green Day’ to raise the funds needed to purchase it. Additional proceeds from the school’s summer fundraiser, ‘HotDogs and Cool Music’, helped to fund the Accelerated Reader programme.

Staff and parents also volunteered to scan and label the library’s collection, while additional items, including the astroturf, were sourced through donations from the local community via Facebook Marketplace.

Jackie Chambers, Head Teacher at Harrietsham Primary School, said, “The school are extremely grateful for the very kind support of Bedfont® and the other members of our local community who have supported us with our library revamp.  They have really helped to bring the children’s vision for their new library to life.  Our thanks also to the staff who have helped and to Mr Walker and Mrs Mannering for their vision and hard work with this project.  This joint project has meant that our children now have the most magical and engaging space to enjoy reading.”

Supporting local initiatives is a key part of Bedfont’s commitment to community engagement, and the company was delighted to contribute to a project that will benefit pupils for many years. To learn more about Bedfont® and its community commitments, visit the website here.

Bedfont® Scientific Limited strengthens its position as world leaders in breath analysis with a new board member

Posted on

Bedfont® appoints Michael Bencak to strengthen its position and accelerate growth.

Bedfont® Scientific Ltd., a world leader in breath analysis, has been designing and manufacturing medical breath analysis devices for almost 50 years and has seen significant growth over the past decade. The innovative med-tech company is pleased to add further experience to its board of directors with the appointment of Michael Bencak. Michael has over 20 years of experience building and leading companies in the global life science and healthcare industries. His strategic approach helps businesses unlock their potential growth and lead them through international expansion.

Bedfont® appoints Michael Bencak
Michael Bencak

Bedfont® works with healthcare professionals worldwide to provide cutting-edge breath analysis medical products to the highest standard, through technical innovation and professional business practice. Working with over 100 distributors worldwide, Bedfont® is leading the way in breath analysis, thanks to its innovative non-invasive devices that aid diagnosis and investigations, ultimately improving patient care worldwide.

“We are delighted to announce the appointment of Michael Bencak to the Board of Bedfont® Scientific Ltd. Michael brings a wealth of international experience in the medical device and life sciences sectors, with a strong track record of scaling businesses, building global partnerships, and driving strategic growth. His insight and leadership will be invaluable as Bedfont® continues its mission to advance breath analysis technology and improve patient care worldwide.” Said Jason Smith, CEO at Bedfont®, “As we enter an exciting new phase of growth, Michael’s appointment strengthens our Board and supports our long-term strategy to expand Bedfont’s global impact in respiratory diagnostics and beyond. Please join us in welcoming Michael to the Bedfont® Board.”

With Keensight’s acquisition of a majority stake in the business back in 2025, the addition of Michael’s experience can only accelerate Bedfont’s growth and move it closer to a world where everyone has access to instant, non-invasive, simple breath testing to aid medical diagnosis.

To learn more about Bedfont® and how it is improving accessibility and healthcare standards worldwide, visit the website here.

Study on inhaler overuse highlights urgent need for better objective asthma monitoring

Posted on

The NObreath® FeNO device offers a clear pathway to more effective asthma care, reducing over-reliance on blue inhalers.

Bedfont® Scientific Limited, an innovative med-tech company specialising in medical breath analysis devices, welcomes the new study at University Hospital Southampton exploring whether enhanced asthma check-ups can reduce inhaler use among children. For over 15 years, Bedfont® has supported improved asthma care with its NObreath® Fractional exhaled Nitric Oxide (FeNO) device, which measures airway inflammation through exhaled breath. The quick and easy test provides clinicians with objective insight to guide medication decisions, reduce unnecessary reliever prescriptions, prevent over-reliance on blue inhalers, and help avoid future asthma attacks.

Research has found that children using 6 or more blue reliever inhalers a year are 3-5 times more likely to have an asthma attack1. Reliever inhalers only treat the immediate symptoms and mask the underlying airway inflammation, which can lead to further exacerbations.

The study aims to create a new alert system that automatically notifies general practitioners (GPs) when a child has been prescribed too many inhalers, prompting an immediate check-up. This will allow healthcare professionals to perform a review and help prevent future attacks.

Jason Smith, CEO at Bedfont®, comments, “We welcome the focus this important study brings to the growing problem of reliever inhaler over-use in children, a clear signal that many young people are still not getting the right support for long-term asthma control. Over-reliance on blue inhalers often reflects unmanaged airway inflammation and missed opportunities for targeted treatment. That’s why we continue to advocate for improving the accessibility of FeNO testing in primary care, a guideline-recommended, evidence-based tool that helps clinicians identify and treat underlying inflammation early. With better access to FeNO testing across the UK, we can help reduce unnecessary reliever use, improve outcomes for children, and support GPs in delivering truly personalised asthma care.”

Although FeNO testing is now recommended as a first-line test in UK asthma guidelines, access remains inconsistent across primary care. As a result, many children continue to be managed without the benefit of objective airway inflammation testing, increasing the risk of poorly controlled asthma and over-reliance on reliever inhalers. Reliever inhaler overuse in children is a well-recognised marker of uncontrolled asthma and is associated with a higher risk of exacerbations and emergency admissions.

NObreath Offers Asthma Pathway

Greater investment and targeted funding are urgently needed to support the widespread adoption of FeNO technology in primary care, helping clinicians deliver earlier, more accurate diagnoses and reduce preventable harm. To learn more about the NObreath® and how it can help asthma care and management, visit the website here.

References

  1. News I. Southampton researchers lead UK-first study to target “dangerous” asthma inhaler overuse [Internet]. ITV News. 2026 [cited 2026 Mar 3]. Available from: https://www.itv.com/news/meridian/2026-02-25/uk-first-study-targets-dangerous-overuse-of-asthma-inhalers-in-children

Giving Opportunity, Gaining Innovation: Women Driving the Future of Med-Tech

Posted on

Bedfont® Scientific Limited believes balanced teams drive better decision-making, stronger innovation, and long-term success.

Bedfont® Scientific Limited, a well-established Med-Tech company with over 49 years of expertise in the design and manufacture of medical breath analysis devices, is celebrating the women driving innovation in the Med-Tech industry this International Women’s Day (IWD). IWD is an annual event that celebrates women’s achievements and raises awareness about gender equality. In 2026, IWD celebrates 115 years of raising awareness of discrimination and taking action to forge gender parity.

International Women's Day 2026

This year’s theme, ‘Give to gain’, highlights the power of reciprocity and support. By giving women equal access to leadership opportunities, Bedfont® has built a diverse and balanced team. Today, women make up 50% of the workforce and nearly half of the companies’ 18 managers, proof that inclusion creates tangible gains for people and performance alike.

Switzerland is leading the way in Med-Tech, with women accounting for 40% of the industry’s workforce1. However, research published in 2024 shows that among the 78 largest medical device companies in Europe, only 24.4% of leadership positions are held by women2, highlighting the ongoing need for greater gender equality at senior levels.

“In a world where women in business have far greater opportunities than in our ancestors’ time, we are now seeing women actively driving the future of MedTech through innovation, leadership and scientific excellence. I am incredibly proud that nearly half of the leadership team at Bedfont are women, clear evidence that inclusion fuels both performance and progress. Representation matters, not only within our industry but for the next generation watching.” Comments Natasha Smith, Chief Operating Director at Bedfont®. “As a mother of two daughters, I want them to grow up proud, strong and confident enough to make their own mark in science, technology and beyond. On this International Women’s Day, with this year’s theme “Give to Gain,” we recognise that by investing in, training and championing women, we are shaping the future of MedTech and creating lasting impact for generations to come.”

This International Women’s Day, Bedfont® is celebrating the strength of a balanced workforce by recognising the women across the organisation with sustainably sourced chocolate from local business N2 Sweets Lab. This initiative reflects the company’s broader commitment to sustainability while supporting both local businesses and third-party partners worldwide, reinforcing a give-to-gain approach that benefits people, communities, and the planet.

To learn more about Bedfont® and its commitment to improving healthcare worldwide, visit the website here.

References

  1. Medtech Sector Study 2024 [Internet]. Swiss Medtech. 2024. Available from: https://www.swiss-medtech.ch/en/news/medtech-sector-study-2024
  2. Kirsh D. Women gain ground in medtech leadership, but parity remains far off [Internet]. Medical Design and Outsourcing. 2025 [cited 2026 Feb 10]. Available from: https://www.medicaldesignandoutsourcing.com/women-gain-ground-in-medtech-leadership-but-parity-remains-far-off/

Bedfont® Scientific Limited partners with Rymindr to deliver vital classroom supplies

Posted on

Bedfont® ensures exercise books reach UK classrooms through sponsorship.

Bedfont® Scientific Limited, a world leader in breath analysis, with nearly 50 years of expertise in the medical device industry, has teamed up with Rymindr, a social-tech company, to deliver vital classroom supplies. Rymindr is an app that lets users track important dates and access rewards. Through the app, Rymindr helps UK schools save money by sharing its profits. Bedfont® is proud to support its exercise book sponsorship campaign by sponsoring 20 boxes of exercise books, ensuring they reach the classrooms where they are needed.

It has been reported that over 70% of schools in the UK are underfunded1, leading to increased pressure on schools through teacher shortages and reduced resources. Rymindr’s mission is to build a single ecosystem that benefits all, leading to positive impacts on society and the environment for this generation and those to come. They have been funding breakfasts, school meals, and classroom supplies for children.

“We’re thrilled to partner with Bedfont® to get essential classroom supplies into UK schools. With budgets under pressure, simple items like classroom resources from exercise books to pencils shouldn’t be a struggle to fund, and this sponsorship will make a real difference in classrooms across the country.” Said Rav Panesar, CEO of Rymindr. “We’re incredibly grateful to Bedfont® for stepping up and sponsoring. This is exactly the kind of community impact we want to create through Rymindr, bringing businesses and schools together to deliver practical support where it’s needed most.”

Bedfont® is supporting their current initiative to get thousands of brand-new exercise books directly into UK primary schools. Having already distributed 4,000 boxes across the country, Rymindr were unfortunately notified at the end of 2025 that their storage facility was being sold. This has led to the launch of their latest sponsorship campaign, inviting individuals and businesses to sponsor boxes of books. The sponsorship covers the practical logistics, such as storage, pallet handling, and distribution.

Bedfont® Helps Deliver Classroom Supplies

“We’re incredibly proud to support this campaign and help deliver something as fundamental as exercise books to classrooms across the UK.” Said Jason Smith, CEO at Bedfont®. “With so many schools facing funding pressures, it’s vital we step in where we can. By sponsoring these boxes, we’re helping teachers focus on what matters most, teaching, while easing some of the financial strain they face every day. Education is the foundation of our future, and we’re committed to playing our part.”

Rymindr is matching each sponsored box, meaning schools across the UK are saving around £100 per box, which will really make a difference to the already stretched school budgets. Bedfont® is strongly committed to supporting the local community and is pleased to assist Rymindr in its latest initiative, providing much-needed exercise books to UK schools. To find out more about Rymindr, visit the website here. For more information on Bedfont® and its community initiatives, visit the website here.

References

  1. New data finds that 7 in 10 schools in England faced budget cuts since 2010 | National Education Union [Internet]. National Education Union. 2025. Available from: https://neu.org.uk/latest/press-releases/new-data-finds-7-10-schools-england-faced-budget-cuts-2010

Bedfont® Scientific Limited is pleased to support a major milestone to improve asthma care

Posted on

Intermedical UK proudly delivers the 3,000th NObreath® FeNO device to the UK market.

Bedfont® Scientific Limited, a medical device manufacturer based in Kent, with over 49 years’ experience in the breath analysis industry, was pleased to support its UK distributor, Intermedical UK, in supplying the 3,000th NObreath® Fractional exhaled Nitric Oxide (FeNO) device in the UK. Intermedical UK, a trusted leader in respiratory health, has been providing cardio-respiratory diagnostic and therapy equipment for frontline care since 1997.

Bedfont® support major milestone in asthma care. Bedfont Supports FeNO Milestone.
Bedfont® and Intermedical Team

Livio Gagliardi, Acting Managing Director at Intermedical (UK) Ltd, said, “Reaching the 3,000th NObreath® FeNO device in the UK is a shared success that reflects the dedication of both the Intermedical and Bedfont® teams. Together, we have worked hard to deliver a clinically proven, accessible, and cost-effective FeNO solution that genuinely meets the needs of frontline healthcare. We are incredibly grateful to our customers for placing their trust in us and for recognising the value that NObreath® brings to asthma diagnosis and ongoing management. Their commitment to improving respiratory care is what makes milestones like this possible, and we look forward to continuing this journey of innovation and impact alongside Bedfont®.”

NObreath FeNO device. Bedfont Supports FeNO Milestone.

The NObreath® FeNO device, manufactured by Bedfont®, is an innovative diagnostic tool that measures airway inflammation and helps healthcare professionals diagnose and manage asthma effectively. With over 3,000 devices now available across the UK, access to FeNO testing is improving, bringing Bedfont® closer to a world where everyone can access instant, non-invasive, and simple breath testing to support medical diagnosis.

As a valued long-term distributor of the NObreath®, Intermedical UK has played a key role in expanding access to high-quality respiratory diagnostics, and the close partnership over the years has been instrumental in reaching this monumental milestone.

Jason Smith, CEO at Bedfont®, comments, “This milestone of 3,000 devices in UK primary care highlights just how rapidly objective asthma testing is advancing. The updated joint UK guidelines now place even greater emphasis on FeNO, echoing the global shift toward evidence-based, accessible diagnostic tools. We are committed to making this technology available everywhere it is needed, ensuring clinicians and patients around the world benefit from fast, non-invasive breath testing.”

Bedfont® remains committed to improving asthma care worldwide, working closely with a global network of distributors to expand access to FeNO testing and improve asthma treatment. Recent partnerships in Mexico and India are already strengthening diagnostic capabilities, enabling clinicians in these regions to integrate simple, non-invasive breath testing into routine asthma assessment.

To learn more about Bedfont® and the NObreath® FeNO device, visit the website here.

coVita™ and Allergy Partners team up to improve asthma care in America

Posted on

Innovative NObreath® FeNO device is the allergists’ device of choice in the USA.

coVita™ LLC, a leader in advanced breath analysis and diagnostic solutions, serves as the U.S. distributor for the innovative NObreath® Fractional Exhaled Nitric Oxide (FeNO) device from UK-based Bedfont® Scientific Ltd. The new agreement with Allergy Partners marks the culmination of a strategic partnership developed over the past two years.

“The partnership established between coVita™ and Allergy Partners marks important progress in broadening access to FeNO technology on a global scale.” Said Jason Smith, CEO at Bedfont®. “We are pleased to support this collaboration and proud of the role coVita™ is playing in advancing high-quality asthma care.”

NObreath® device is allergists' device of choice in the USA.
Taking a FeNO test with the NObreath®

As the nation’s largest and most trusted integrated network of allergy and asthma specialists, Allergy Partners serves patients through more than 125 locations in over 20 states. Under the new agreement, all Allergy Partners clinics will provide FeNO testing with the NObreath® device, enhancing patient access to advanced, non-invasive tools that aid in asthma diagnosis and management. The NObreath® is the allergist’s device of choice in the USA, further underscoring its value in supporting accurate assessment and personalised treatment. With 26.8 million Americans, 8.2% of the U.S. population, affected by asthma in 2022, the need for innovative tools to support better care and disease management has never been greater.

“We are incredibly proud of our collaboration with Allergy Partners and thrilled to help them implement the NObreath® FeNO technology”, said Jason Aversano, CEO at coVita™.  “Their determination to integrate FeNO testing across their entire network of providers is illustrative of their understanding of the vital role objective FeNO monitoring plays in the modern clinical setting.”

Bedfont® Scientific, manufacturer of the NObreath®, and coVita™, share a long-standing partnership grounded in mutual respect, trust, and a shared vision to improve respiratory health through innovation. Over the years, the two companies have worked hand in hand to make advanced breath analysis more accessible to clinicians and patients throughout the United States. Their collaboration continues to exemplify how aligned values and global cooperation can drive meaningful change in healthcare.

To learn more about the NObreath® FeNO device, visit the website here.

References

  1. CDC. Most Recent Asthma Data [Internet]. Asthma Data. 2024. Available from: https://www.cdc.gov/asthma-data/about/most-recent-asthma-data.html

Bedfont® Scientific Limited is proud to exhibit cutting-edge breath analysis devices at WHX Dubai.

Posted on

Smokerlyzer®, Gastrolyzer®, and NObreath® devices on show at the world’s largest healthcare event.

Bedfont® Scientific, world leaders in breath analysis, with over 49 years of experience in the medical breath analysis industry, is thrilled to be showing its innovative devices at this year’s World Health Expo (WHX) Dubai, from the 9th to the 12th February 2026. Formally known as Arab Health, WHX Dubai has grown into a global healthcare hub, attracting professionals from over 180 countries. The event is due to take place at the Dubai Exhibition Centre.

Bedfont® exhibit at WHX Dubai
Bedfont Team at Arab Health 2025

WHX Dubai represents a cornerstone event for international healthcare collaboration, innovation, investment, and knowledge sharing. Bedfont® is pleased to be demonstrating its devices at the world’s largest healthcare event. On show at stand S7.F90.F, you will find the Smokerlyzer® range of breath carbon monoxide (CO) devices, which aid smoking cessation. The Gastrolyzer® hydrogen-methane breath testing (HMBT) range, which is used to help detect gastrointestinal disorders. And the NObreath® fractional exhaled nitric oxide (FeNO) device, which aids asthma diagnosis and management.

Jason Smith, CEO at Bedfont® Scientific, said, “WHX Dubai continues to set the benchmark for healthcare innovation worldwide. Our presence underscores our dedication to excellence and to delivering devices that genuinely elevate the standard of patient care. As healthcare demands grow, we remain committed to providing solutions that empower clinicians, improve outcomes, and support a more efficient, responsive care environment. We look forward to building on the momentum generated at this year’s event.”

WHX Dubai 2026 is expected to attract over 235,000 professionals, offering the opportunity to see innovative medical solutions, attend educational and thought-leadership conferences, and network with like-minded individuals looking to improve healthcare across the globe. With strong relationships already established across the Middle East, Bedfont® hopes to engage with various healthcare professionals during the event, showcasing its innovative breath analysis devices.

You will find the friendly Bedfont® team at stand S7.F90.F. For more information on Bedfont® and to learn more about the Smokerlyzer®, Gastrolyzer®, and NObreath® devices, visit the website here.

Back to top